A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Bristol-Myers Squibb13 enrolled

Overview

The purpose of this study is to assess the dose limiting toxicity (DLT) of BMS-582664 and the maximum tolerated dose(MTD) in subjects with advanced or metastatic solid tumors.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Solid Tumors

Interventions

BrivanibDRUG

Tablet, Oral, Brivanib 300 mg, 600 mg, 800 mg, 1000 mg, once daily (cycle 1: Day 1, Day 8 - 35), more than 5 weeks depending on response/toxicity

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must have measurable disease * Documented failure to standard therapies exist, or which are determined to be inappropriate by the investigator * ECOG PS: 0-1 Exclusion Criteria: * Subjects with centrally located squamous cell carcinoma of the lung

Locations (1)

Local Institution

Sunto-Gun, Shizuoka, Japan

Outcomes

Primary Outcomes

Dose Limiting Toxicity

Time frame: at the end of the first cycle of the study

Maximum Tolerated Dose

Time frame: at the end of the first cycle of the study

Secondary Outcomes

To assess any preliminary evidence of anti-tumor activity observed with BMS-582664

Time frame: at the end of the study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.